Skip to Main Content

Greetings, everyone. Damian Garde here once more, filling in for Ed Silverman to bring you headlines from around the pharma universe as we head into a long weekend.

FDA Commissioner Dr. Robert Califf hasn’t heard a peep from the Trump transition team. That’s according to this interview with The Washington Post, in which the former Duke cardiologist says he’ll be content no matter what happens. “Everyone who knows me knows I have just had fun every day on the job,” Califf told the Post. In the meantime, Califf took pains to point out how it important it is that the FDA determine whether medicines work before approving them, comments perhaps aimed at any potential successors who might take a more laissez-faire approach to the agency.


All is not well at South Korea’s Hanmi Pharmaceutical, which once seemed to be a rising star in the global drug industry. Last year, Sanofi agreed to pay the company as much as $4.2 billion in exchange for the rights to three diabetes drugs. That deal has since unwound, as Sanofi has returned one of the treatments in question, scaled back its future payouts, and pushed Hanmi to give back some of its upfront payment, The Korea Times says. In September, Boehringer Ingelheim terminated a similar agreement with Hanmi, and the company’s share price has since fallen by more than 50 percent.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!